In-silico guided identification and studies of potential FFAR4 agonists for type 2 diabetes mellitus therapy.

Journal: Expert opinion on drug discovery
Published Date: Jun 28, 2025

Abstract

BACKGROUND: The activation of free fatty acid receptor 4 (FFAR4) enhances insulin sensitivity and glucose uptake while mitigating inflammation. It is a promising therapeutic approach for managing type 2 diabetes mellitus (T2DM).

Authors

  • Divya Jhinjharia
    School of Biotechnology, Gautam Buddha University, Greater Noida, India.
  • Pinky Juneja
    Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
  • Gaurava Srivastava
    Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
  • Kiran Bharat Lokhande
    Translational Bioinformatics and Computational Genomics Research Lab, Department of Life Sciences, Shiv Nadar Institution of Eminence, Greater Noida, India.
  • Aarti Sharma
    School of Sciences, Indira Gandhi National Open University, Maidan Garhi, New Delhi 110068, India.
  • Jitendra Singh Rathore
    School of Biotechnology, Gautam Buddha University, Greater Noida, India.
  • Savneet Kaur
    Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
  • Shakti Sahi
    School of Biotechnology, Gautam Buddha University, Greater Noida, India.

Keywords

External Resources

Popular Topics
Recent Journals